Toll-Like Receptor 2 (TLR2) Polymorphisms Are Associated with Reversal Reaction in Leprosy
Background. Leprosy is characterized by a spectrum of clinical manifestations that depend on the type of immune response against the pathogen. Patients may undergo immunological changes known as “reactional states” (reversal reaction and erythema nodosum leprosum) that result in major clinical deter...
Saved in:
Published in | The Journal of infectious diseases Vol. 197; no. 2; pp. 253 - 261 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Chicago, IL
The University of Chicago Press
15.01.2008
University of Chicago Press |
Subjects | |
Online Access | Get full text |
ISSN | 0022-1899 1537-6613 |
DOI | 10.1086/524688 |
Cover
Abstract | Background. Leprosy is characterized by a spectrum of clinical manifestations that depend on the type of immune response against the pathogen. Patients may undergo immunological changes known as “reactional states” (reversal reaction and erythema nodosum leprosum) that result in major clinical deterioration. The goal of the present study was to assess the effect of Toll-like receptor 2 (TLR2) polymorphisms on susceptibility to and clinical presentation of leprosy. Methods. Three polymorphisms in TLR2 (597C→T, 1350T→C, and a microsatellite marker) were analyzed in 431 Ethiopian patients with leprosy and 187 control subjects. The polymorphism-associated risk of developing leprosy, lepromatous (vs. tuberculoid) leprosy, and leprosy reactions was assessed by multivariate logistic regression models. Results. The microsatellite and the 597C→T polymorphisms both influenced susceptibility to reversal reaction. Although the 597T allele had a protective effect (odds ratio [OR], 0.34 [95% confidence interval {CI}, 0.17–0.68]; P = .002 under the dominant model), homozygosity for the 280-bp allelic length of the microsatellite strongly increased the risk of reversal reaction (OR, 5.83 [95% CI, 1.98–17.15]; P = .001 under the recessive model). These associations were consistent among 3 different ethnic groups. Conclusions. These data suggest a significant role for TLR-2 in the occurrence of leprosy reversal reaction and provide new insights into the immunogenetics of the disease. |
---|---|
AbstractList | Background.
Leprosy is characterized by a spectrum of clinical manifestations that depend on the type of immune response against the pathogen. Patients may undergo immunological changes known as "reactional states" (reversal reaction and erythema nodosum leprosum) that result in major clinical deterioration. The goal of the present study was to assess the effect of Toll-like receptor 2 (TLR2) polymorphisms on susceptibility to and clinical presentation of leprosy.
Methods.
Three polymorphisms in TLR2 (597C→T, 1350T→C, and a microsatellite marker) were analyzed in 431 Ethiopian patients with leprosy and 187 control subjects. The polymorphism-associated risk of developing leprosy, lepromatous (vs. tuberculoid) leprosy, and leprosy reactions was assessed by multivariate logistic regression models.
Results.
The microsatellite and the 597C→T polymorphisms both influenced susceptibility to reversal reaction. Although the 597T allele had a protective effect (odds ratio [OR], 0.34 [95% confidence interval {CI}, 0.17-0.68]; P = .002 under the dominant model), homozygosity for the 280-bp allelic length of the microsatellite strongly increased the risk of reversal reaction (OR, 5.83 [95% CI, 1.98-17.15]; P = .001 under the recessive model). These associations were consistent among 3 different ethnic groups.
Conclusions.
These data suggest a significant role for TLR-2 in the occurrence of leprosy reversal reaction and provide new insights into the immunogenetics of the disease. Leprosy is characterized by a spectrum of clinical manifestations that depend on the type of immune response against the pathogen. Patients may undergo immunological changes known as "reactional states" (reversal reaction and erythema nodosum leprosum) that result in major clinical deterioration. The goal of the present study was to assess the effect of Toll-like receptor 2 (TLR2) polymorphisms on susceptibility to and clinical presentation of leprosy.BACKGROUNDLeprosy is characterized by a spectrum of clinical manifestations that depend on the type of immune response against the pathogen. Patients may undergo immunological changes known as "reactional states" (reversal reaction and erythema nodosum leprosum) that result in major clinical deterioration. The goal of the present study was to assess the effect of Toll-like receptor 2 (TLR2) polymorphisms on susceptibility to and clinical presentation of leprosy.Three polymorphisms in TLR2 (597C-->T, 1350T-->C, and a microsatellite marker) were analyzed in 431 Ethiopian patients with leprosy and 187 control subjects. The polymorphism-associated risk of developing leprosy, lepromatous (vs. tuberculoid) leprosy, and leprosy reactions was assessed by multivariate logistic regression models.METHODSThree polymorphisms in TLR2 (597C-->T, 1350T-->C, and a microsatellite marker) were analyzed in 431 Ethiopian patients with leprosy and 187 control subjects. The polymorphism-associated risk of developing leprosy, lepromatous (vs. tuberculoid) leprosy, and leprosy reactions was assessed by multivariate logistic regression models.The microsatellite and the 597C-->T polymorphisms both influenced susceptibility to reversal reaction. Although the 597T allele had a protective effect (odds ratio [OR], 0.34 [95% confidence interval {CI}, 0.17-0.68]; P= .002 under the dominant model), homozygosity for the 280-bp allelic length of the microsatellite strongly increased the risk of reversal reaction (OR, 5.83 [95% CI, 1.98-17.15]; P= .001 under the recessive model). These associations were consistent among 3 different ethnic groups.RESULTSThe microsatellite and the 597C-->T polymorphisms both influenced susceptibility to reversal reaction. Although the 597T allele had a protective effect (odds ratio [OR], 0.34 [95% confidence interval {CI}, 0.17-0.68]; P= .002 under the dominant model), homozygosity for the 280-bp allelic length of the microsatellite strongly increased the risk of reversal reaction (OR, 5.83 [95% CI, 1.98-17.15]; P= .001 under the recessive model). These associations were consistent among 3 different ethnic groups.These data suggest a significant role for TLR-2 in the occurrence of leprosy reversal reaction and provide new insights into the immunogenetics of the disease.CONCLUSIONSThese data suggest a significant role for TLR-2 in the occurrence of leprosy reversal reaction and provide new insights into the immunogenetics of the disease. Background. Leprosy is characterized by a spectrum of clinical manifestations that depend on the type of immune response against the pathogen. Patients may undergo immunological changes known as "reactional states" (reversal reaction and erythema nodosum leprosum) that result in major clinical deterioration. The goal of the present study was to assess the effect of Toll-like receptor 2 (TLR2) polymorphisms on susceptibility to and clinical presentation of leprosy. Methods. Three polymorphisms in TLR2 (597C→T, 1350T→C, and a microsatellite marker) were analyzed in 431 Ethiopian patients with leprosy and 187 control subjects. The polymorphism-associated risk of developing leprosy, lepromatous (vs. tuberculoid) leprosy, and leprosy reactions was assessed by multivariate logistic regression models. Results. The microsatellite and the 597C→T polymorphisms both influenced susceptibility to reversal reaction. Although the 597T allele had a protective effect (odds ratio [OR], 0.34 [95% confidence interval {CI}, 0.17-0.68]; P= .002 under the dominant model), homozygosity for the 280-bp allelic length of the microsatellite strongly increased the risk of reversal reaction (OR, 5.83 [95% CI, 1.98-17.15]; P= .001 under the recessive model). These associations were consistent among 3 different ethnic groups. Conclusions. These data suggest a significant role for TLR-2 in the occurrence of leprosy reversal reaction and provide new insights into the immunogenetics of the disease. Background. Leprosy is characterized by a spectrum of clinical manifestations that depend on the type of immune response against the pathogen. Patients may undergo immunological changes known as "reactional states" (reversal reaction and erythema nodosum leprosum) that result in major clinical deterioration. The goal of the present study was to assess the effect of Toll-like receptor 2 (TLR2) polymorphisms on susceptibility to and clinical presentation of leprosy. Methods. Three polymorphisms in TLR2 (597C1T, 1350T1C, and a microsatellite marker) were analyzed in 431 Ethiopian patients with leprosy and 187 control subjects. The polymorphism-associated risk of developing leprosy, lepromatous (vs. tuberculoid) leprosy, and leprosy reactions was assessed by multivariate logistic regression models. Results. The microsatellite and the S97C1T polymorphisms both influenced susceptibility to reversal reaction. Although the 597T allele had a protective effect (odds ratio [OR], 0.34 [95% confidence interval {CI}, 0.17-0.68]; P = .002 under the dominant model), homozygosity for the 280-bp allelic length of the microsatellite strongly increased the risk of reversal reaction (OR, 5.83 [95% a, 1.98-17.15]; P .001 under the recessive model). These associations were consistent among 3 different ethnic groups. Conclusions. These data suggest a significant role for TLR-2 in the occurrence of leprosy reversal reaction and provide new insights into the immunogenetics of the disease. Leprosy is characterized by a spectrum of clinical manifestations that depend on the type of immune response against the pathogen. Patients may undergo immunological changes known as "reactional states" (reversal reaction and erythema nodosum leprosum) that result in major clinical deterioration. The goal of the present study was to assess the effect of Toll-like receptor 2 (TLR2) polymorphisms on susceptibility to and clinical presentation of leprosy. Three polymorphisms in TLR2 (597C-->T, 1350T-->C, and a microsatellite marker) were analyzed in 431 Ethiopian patients with leprosy and 187 control subjects. The polymorphism-associated risk of developing leprosy, lepromatous (vs. tuberculoid) leprosy, and leprosy reactions was assessed by multivariate logistic regression models. The microsatellite and the 597C-->T polymorphisms both influenced susceptibility to reversal reaction. Although the 597T allele had a protective effect (odds ratio [OR], 0.34 [95% confidence interval {CI}, 0.17-0.68]; P= .002 under the dominant model), homozygosity for the 280-bp allelic length of the microsatellite strongly increased the risk of reversal reaction (OR, 5.83 [95% CI, 1.98-17.15]; P= .001 under the recessive model). These associations were consistent among 3 different ethnic groups. These data suggest a significant role for TLR-2 in the occurrence of leprosy reversal reaction and provide new insights into the immunogenetics of the disease. |
Author | Britton, Sven Hawn, Thomas R. Saunderson, Paul Abraham, Isaac Zhao, Lue Ping Bochud, Pierre-Yves Argaw, Azeb Tadesse Janer, Marta Aderem, Alan Siddiqui, M. Ruby Kaplan, Gilla |
AuthorAffiliation | 3 Quantitative Genetic Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle 2 Department of Medicine, University of Washington, Seattle 6 Armauer Hansen Research Institute, Addis Ababa, Ethiopia 5 All-Africa Leprosy Rehabilitation and Training Centre 4 Public Health Research Institute, Laboratory of Mycobacterial Immunity and Pathogenesis, University of Medicine and Dentistry of New Jersey, Newark 1 Institute for Systems Biology, University of Washington, Seattle |
AuthorAffiliation_xml | – name: 2 Department of Medicine, University of Washington, Seattle – name: 6 Armauer Hansen Research Institute, Addis Ababa, Ethiopia – name: 1 Institute for Systems Biology, University of Washington, Seattle – name: 3 Quantitative Genetic Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle – name: 5 All-Africa Leprosy Rehabilitation and Training Centre – name: 4 Public Health Research Institute, Laboratory of Mycobacterial Immunity and Pathogenesis, University of Medicine and Dentistry of New Jersey, Newark |
Author_xml | – sequence: 1 givenname: Pierre-Yves surname: Bochud fullname: Bochud, Pierre-Yves email: pyb@systemsbiology.org organization: Institute for Systems Biology, Fred Hutchinson Cancer Research Center, Seattle – sequence: 2 givenname: Thomas R. surname: Hawn fullname: Hawn, Thomas R. organization: Institute for Systems Biology, Fred Hutchinson Cancer Research Center, Seattle – sequence: 3 givenname: M. Ruby surname: Siddiqui fullname: Siddiqui, M. Ruby organization: Public Health Research Institute, Laboratory of Mycobacterial Immunity and Pathogenesis, University of Medicine and Dentistry of New Jersey, Newark – sequence: 4 givenname: Paul surname: Saunderson fullname: Saunderson, Paul organization: All-Africa Leprosy Rehabilitation and Training Centre, Addis Ababa, Ethiopia – sequence: 5 givenname: Sven surname: Britton fullname: Britton, Sven organization: Armauer Hansen Research Institute, Addis Ababa, Ethiopia – sequence: 6 givenname: Isaac surname: Abraham fullname: Abraham, Isaac organization: Armauer Hansen Research Institute, Addis Ababa, Ethiopia – sequence: 7 givenname: Azeb Tadesse surname: Argaw fullname: Argaw, Azeb Tadesse organization: Armauer Hansen Research Institute, Addis Ababa, Ethiopia – sequence: 8 givenname: Marta surname: Janer fullname: Janer, Marta organization: Institute for Systems Biology, Fred Hutchinson Cancer Research Center, Seattle – sequence: 9 givenname: Lue Ping surname: Zhao fullname: Zhao, Lue Ping organization: Quantitative Genetic Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle – sequence: 10 givenname: Gilla surname: Kaplan fullname: Kaplan, Gilla organization: Public Health Research Institute, Laboratory of Mycobacterial Immunity and Pathogenesis, University of Medicine and Dentistry of New Jersey, Newark – sequence: 11 givenname: Alan surname: Aderem fullname: Aderem, Alan organization: Institute for Systems Biology, Fred Hutchinson Cancer Research Center, Seattle |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20028701$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18177245$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkl2LEzEYhYOsuN1V_4EyXigKjuZrkvRGKEVdoaiUCrI3IZt5x2Y3MxmT6Wr_vSlTu34gXiVwnpycvCcn6KgLHSB0n-AXBCvxsqJcKHULTUjFZCkEYUdogjGlJVHT6TE6SekSY8yZkHfQMVFESsqrCTpfBe_LhbuCYgkW-iHEghZPV4slfVZ8DH7bhtivXWpTMYtQzFIK1pkB6uKbG9b5zDXEZHzeGDu40BWuKxbQx5C2d9HtxvgE9_brKfr05vVqflYuPrx9N58tSpujDmXNwV40pmmqSlrAjHKpBCVAamtkzTkHJg0TRhkLvAYqgAGV0gghDKkZY6fo1ejbby5aqC10QzRe99G1Jm51ME7_rnRurb-Ea81wHsK0ygZP9gYxfN1AGnTrkgXvTQdhk7TEFCtF-H9BiikjrNqBD3-NdMjyc-4ZeLwHTLLGN9F01qUDR3NzSmJyc6PNE00RmhsrrHfF67H4DD7_A7RuMLtG8pOd_xt_NOJh0__b8sHIXKb8Kw4Uw1hJUYmsl6Pu0gDfD7qJV1pIJit99vlcz6l8PyfLqabsBzGwz-c |
CODEN | JIDIAQ |
CitedBy_id | crossref_primary_10_1371_journal_pone_0175180 crossref_primary_10_3390_molecules200815392 crossref_primary_10_1128_MMBR_00025_10 crossref_primary_10_1590_0074_02760160366 crossref_primary_10_1016_j_inhe_2011_09_006 crossref_primary_10_3389_fimmu_2024_1298749 crossref_primary_10_3389_fmed_2022_865330 crossref_primary_10_3389_fimmu_2018_01223 crossref_primary_10_1002_jgm_2971 crossref_primary_10_1146_annurev_immunol_030409_101335 crossref_primary_10_1371_journal_pntd_0004345 crossref_primary_10_3389_fgene_2022_952219 crossref_primary_10_1016_j_antinf_2012_09_001 crossref_primary_10_1371_journal_pone_0058687 crossref_primary_10_2217_fmb_10_173 crossref_primary_10_1007_s00439_012_1153_7 crossref_primary_10_1093_infdis_jis208 crossref_primary_10_2165_11311110_000000000_00000 crossref_primary_10_1111_j_1365_3083_2012_02681_x crossref_primary_10_1155_2012_415057 crossref_primary_10_1155_2019_3405103 crossref_primary_10_1097_QCO_0b013e32833c2209 crossref_primary_10_3109_08830185_2013_777064 crossref_primary_10_1590_S0074_02762012000900028 crossref_primary_10_1016_j_jdermsci_2016_01_001 crossref_primary_10_3389_fmed_2023_1233220 crossref_primary_10_1016_j_smim_2018_06_003 crossref_primary_10_1371_journal_pone_0024370 crossref_primary_10_1590_S0074_02762012000900020 crossref_primary_10_1128_IAI_00816_09 crossref_primary_10_1093_infdis_jir521 crossref_primary_10_1371_journal_pntd_0001869 crossref_primary_10_2119_molmed_2009_00097 crossref_primary_10_3389_fphar_2024_1361641 crossref_primary_10_1016_j_intimp_2018_03_002 crossref_primary_10_1111_j_1365_2133_2012_10891_x crossref_primary_10_1590_0074_02760180274 crossref_primary_10_1038_gene_2011_49 crossref_primary_10_1371_journal_pgen_1003578 crossref_primary_10_2217_fmb_11_39 crossref_primary_10_1016_j_biopha_2012_05_001 crossref_primary_10_2217_pgs_09_121 crossref_primary_10_3109_10408363_2011_641517 crossref_primary_10_1016_j_jdermsci_2008_11_001 crossref_primary_10_3389_fmed_2021_713143 crossref_primary_10_1111_j_1365_4632_2009_04111_x crossref_primary_10_1016_j_dld_2012_08_006 crossref_primary_10_1186_1297_9716_44_50 crossref_primary_10_1016_j_meegid_2017_03_015 crossref_primary_10_4103_AJPD_AJPD_8_24 crossref_primary_10_1097_INF_0b013e31818de21e crossref_primary_10_1186_1475_2875_8_50 crossref_primary_10_1038_nrd3087 crossref_primary_10_1051_medsci_2010263281 crossref_primary_10_1016_j_clindermatol_2014_10_001 crossref_primary_10_1517_17530059_2013_786039 crossref_primary_10_3390_ani11071912 crossref_primary_10_1007_s10875_012_9770_4 crossref_primary_10_1371_journal_pntd_0000231 crossref_primary_10_1007_s00439_019_02087_5 crossref_primary_10_1371_journal_pntd_0002015 crossref_primary_10_1016_j_patbio_2013_03_003 crossref_primary_10_1016_j_vetimm_2010_06_015 crossref_primary_10_1016_S0011_393X_10_80005_0 crossref_primary_10_1093_carcin_bgn262 crossref_primary_10_1177_00494755231210724 crossref_primary_10_1371_journal_pone_0029747 crossref_primary_10_1016_j_humimm_2010_07_001 crossref_primary_10_1016_j_mehy_2011_10_022 crossref_primary_10_1016_j_vetimm_2008_12_007 crossref_primary_10_4103_ejdv_ejdv_50_23 crossref_primary_10_1097_SHK_0b013e3181eb45b3 crossref_primary_10_1016_j_clindermatol_2015_10_005 crossref_primary_10_1007_s00439_013_1273_8 crossref_primary_10_1128_IAI_00121_12 crossref_primary_10_1016_j_clindermatol_2014_07_005 crossref_primary_10_1186_1471_2156_10_21 crossref_primary_10_3389_fimmu_2018_00518 crossref_primary_10_3390_tropicalmed8100473 crossref_primary_10_1136_bmjopen_2013_004239 crossref_primary_10_1007_s10096_009_0746_0 crossref_primary_10_1590_S0365_05962011000400013 crossref_primary_10_1093_hmg_ddt286 crossref_primary_10_1016_j_abd_2021_08_006 crossref_primary_10_3389_fmed_2021_694376 crossref_primary_10_1111_j_1365_4632_2011_04961_x crossref_primary_10_1007_s12026_015_8640_6 crossref_primary_10_1093_infdis_jit133 crossref_primary_10_1016_j_humimm_2013_04_009 crossref_primary_10_1016_S0001_4079_19_32064_3 crossref_primary_10_1097_MAJ_0b013e318232a6cf crossref_primary_10_1186_1475_2875_11_47 crossref_primary_10_1080_08830185_2020_1851370 crossref_primary_10_1155_2011_923943 crossref_primary_10_3389_fimmu_2018_01674 crossref_primary_10_1038_nrd3203 crossref_primary_10_1093_infdis_jiu612 crossref_primary_10_3389_fimmu_2015_00658 crossref_primary_10_1590_abd1806_4841_20142450 crossref_primary_10_1371_journal_pgen_1006637 crossref_primary_10_1016_j_micinf_2012_03_004 crossref_primary_10_1073_pnas_1901805116 crossref_primary_10_1155_2013_459169 crossref_primary_10_1586_1744666X_2015_1012501 |
Cites_doi | 10.1016/S0928-8244(03)00342-0 10.1038/nrg1916 10.1038/86958 10.1086/315174 10.1007/s00439-004-1249-9 10.1111/j.1399-0039.1997.tb02731.x 10.1038/nri1246 10.1016/S1473-3099(07)70185-8 10.1038/sj.gene.6363926 10.1086/519693 10.1385/IR:28:2:109 10.1016/j.cell.2006.02.015 10.1073/pnas.0409831102 10.4049/jimmunol.170.7.3451 10.1126/science.1925582 10.1086/514853 10.1183/09031936.03.00061703 10.1038/nature02761 10.1038/nature02326 10.1128/CMR.19.2.338-381.2006 10.1146/annurev.immunol.20.081501.125851 10.1111/j.1574-695X.2001.tb01586.x 10.1093/nar/gkh005 10.1126/science.1681588 10.1038/sj.gene.6364274 10.1086/513830 10.4049/jimmunol.149.4.1470 10.1086/517282 10.1002/gepi.1370120107 10.1038/nm864 |
ContentType | Journal Article |
Copyright | Copyright 2007 Infectious Diseases Society of America 2008 by the Infectious Diseases Society of America 2008 2008 INIST-CNRS 2008 by the Infectious Diseases Society of America. All rights reserved. 2008 |
Copyright_xml | – notice: Copyright 2007 Infectious Diseases Society of America – notice: 2008 by the Infectious Diseases Society of America 2008 – notice: 2008 INIST-CNRS – notice: 2008 by the Infectious Diseases Society of America. All rights reserved. 2008 |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL 7T5 C1K H94 7X8 5PM |
DOI | 10.1086/524688 |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Immunology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1537-6613 |
EndPage | 261 |
ExternalDocumentID | PMC3077295 18177245 20028701 10_1086_524688 10.1086/524688 30087656 ark_67375_HXZ_C27NC1R9_2 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GeographicLocations | Ethiopia |
GeographicLocations_xml | – name: Ethiopia |
GrantInformation_xml | – fundername: NIAID NIH HHS grantid: U54 AI054523 – fundername: NIAID NIH HHS grantid: AI25032 – fundername: NIAID NIH HHS grantid: AI22616 – fundername: NIAID NIH HHS grantid: R37 AI025032 – fundername: NIAID NIH HHS grantid: R01 AI032972 – fundername: NIAID NIH HHS grantid: R01 AI025032 – fundername: National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID grantid: R01 AI025032-24 || AI – fundername: National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID grantid: U54 AI054523-01 || AI – fundername: National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID grantid: R01 AI032972-20 || AI |
GroupedDBID | --- -DZ -~X ..I .2P .I3 .XZ .ZR 08P 0R~ 123 1TH 29K 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 70D 85S AABZA AACGO AACZT AAHBH AAHTB AAJKP AAJQQ AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWTL ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPEJ ABPLY ABPPZ ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ABZBJ ACGFO ACGFS ACGOD ACHIC ACPRK ACUFI ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFIYH AFOFC AFXAL AFYAG AGINJ AGKEF AGORE AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQVQM ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BR6 BSCLL BTRTY BVRKM C45 CDBKE CS3 CZ4 D-I DAKXR DCCCD DIK DILTD DU5 D~K EBS ECGQY EE~ EJD EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HQ3 HTVGU HW0 HZ~ IH2 IOX IPSME J21 JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B LSO LU7 MHKGH MJL ML0 N4W N9A NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TR2 W2D W8F WH7 X7H YAYTL YKOAZ YXANX ~91 AAYOK AASNB ADACV ADJQC ADRIX AFXEN DOOOF ESX JSODD M49 AAYXX CITATION .55 .GJ 1KJ 3O- 41~ AAFWJ AAPGJ AAWDT ABDPE ABSMQ ACFRR ACPQN ACUTJ ACVCV ACZBC ADMTO AEKPW AFFQV AFHKK AFQQW AFSHK AGKRT AGMDO AHGBF AI. AJDVS APJGH AQDSO AQKUS AVNTJ BZKNY EIHJH IQODW J5H MBLQV MVM NEJ OBFPC O~Y P0- TMA VH1 X7M Y6R ZE2 ZGI ZXP CGR CUY CVF ECM EIF NPM 7QL 7T5 C1K H94 7X8 5PM |
ID | FETCH-LOGICAL-c537t-d4ecbfaff557ce032478621e1dca7d444e37a36a8ace4de26e3e277a666a1d333 |
ISSN | 0022-1899 |
IngestDate | Thu Aug 21 14:12:06 EDT 2025 Sat Sep 27 16:48:09 EDT 2025 Sun Sep 28 10:49:55 EDT 2025 Fri May 30 11:01:06 EDT 2025 Mon Jul 21 09:14:52 EDT 2025 Thu Apr 24 23:04:10 EDT 2025 Tue Jul 01 03:23:59 EDT 2025 Wed Sep 11 04:51:03 EDT 2024 Fri Jun 20 02:32:04 EDT 2025 Sat Sep 20 11:01:42 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Infection Skin disease Bacteriosis Leprosy Toll like receptor Mycobacterial infection Leprosy reaction Polymorphism |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c537t-d4ecbfaff557ce032478621e1dca7d444e37a36a8ace4de26e3e277a666a1d333 |
Notes | ark:/67375/HXZ-C27NC1R9-2 Present affiliations: Centre for Infections, Health Protection Agency, London, United Kingdom (M.R.S.); American Leprosy Missions, Greenville, South Carolina (P.S.); Department of Medicine, Karolinska Institute, Stockholm, Sweden (S.B.); Mount Sinai School of Medicine, New York, New York (A.T.A.). istex:335E27CF66A6C07B7A6BAED5BBD9B84721CF6200 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://academic.oup.com/jid/article-pdf/197/2/253/18051290/197-2-253.pdf |
PMID | 18177245 |
PQID | 20231354 |
PQPubID | 23462 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3077295 proquest_miscellaneous_70208814 proquest_miscellaneous_20231354 pubmed_primary_18177245 pascalfrancis_primary_20028701 crossref_primary_10_1086_524688 crossref_citationtrail_10_1086_524688 oup_primary_10_1086_524688 jstor_primary_30087656 istex_primary_ark_67375_HXZ_C27NC1R9_2 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2008-01-15 |
PublicationDateYYYYMMDD | 2008-01-15 |
PublicationDate_xml | – month: 01 year: 2008 text: 2008-01-15 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | Chicago, IL |
PublicationPlace_xml | – name: Chicago, IL – name: United States |
PublicationTitle | The Journal of infectious diseases |
PublicationTitleAbbrev | The Journal of Infectious Diseases |
PublicationTitleAlternate | The Journal of Infectious Diseases |
PublicationYear | 2008 |
Publisher | The University of Chicago Press University of Chicago Press |
Publisher_xml | – name: The University of Chicago Press – name: University of Chicago Press |
References | rf25_321 rf36_331 Rajalingam R (rf33_328) 1997; 49 rf14_310 rf37_332 rf2_298 rf30_325 rf18_314 Saunderson P (rf19_315) 2000; 71 Abel L (rf34_329) 1998; 177 rf26_322 rf15_311 rf12_308 rf3_299 rf9_305 Ridley DS (rf1_297) 1966; 34 Roy S (rf32_327) 1997; 176 rf10_306 rf17_313 rf28_324 rf38_333 Schreuder PA (rf6_302) 1998; 66 rf27_323 rf4_300 rf8_304 de Rijk AJ (rf20_316) 1994; 65 Jopling WH (rf21_317) 1981; 52 rf16_312 rf31_326 Yamamura M (rf5_301) 1992; 149 de Rijk AJ (rf22_318) 1994; 65 Bochud P-Y (rf13_309) 2003; 170 rf11_307 rf24_320 rf35_330 rf7_303 Saunderson P (rf23_319) 2000; 71 |
References_xml | – ident: rf15_311 doi: 10.1016/S0928-8244(03)00342-0 – volume: 34 start-page: 255 year: 1966 ident: rf1_297 publication-title: Int J Lepr Other Mycobact Dis – ident: rf38_333 doi: 10.1038/nrg1916 – volume: 65 start-page: 320 year: 1994 ident: rf22_318 publication-title: Lepr Rev – ident: rf9_305 doi: 10.1038/86958 – ident: rf36_331 doi: 10.1086/315174 – volume: 65 start-page: 305 year: 1994 ident: rf20_316 publication-title: Lepr Rev – ident: rf27_323 doi: 10.1007/s00439-004-1249-9 – volume: 71 start-page: 273 year: 2000 ident: rf19_315 publication-title: Lepr Rev – volume: 49 start-page: 168 year: 1997 ident: rf33_328 publication-title: Tissue Antigens doi: 10.1111/j.1399-0039.1997.tb02731.x – ident: rf12_308 doi: 10.1038/nri1246 – ident: rf17_313 doi: 10.1016/S1473-3099(07)70185-8 – ident: rf7_303 doi: 10.1038/sj.gene.6363926 – ident: rf18_314 doi: 10.1086/519693 – volume: 66 start-page: 159 year: 1998 ident: rf6_302 publication-title: Reactions. Int J Lepr Other Mycobact Dis – ident: rf8_304 doi: 10.1385/IR:28:2:109 – ident: rf10_306 doi: 10.1016/j.cell.2006.02.015 – ident: rf26_322 doi: 10.1073/pnas.0409831102 – volume: 170 start-page: 3451 year: 2003 ident: rf13_309 publication-title: J Immunol doi: 10.4049/jimmunol.170.7.3451 – ident: rf3_299 doi: 10.1126/science.1925582 – ident: rf24_320 doi: 10.1086/514853 – ident: rf14_310 doi: 10.1183/09031936.03.00061703 – ident: rf11_307 doi: 10.1038/nature02761 – volume: 52 start-page: 273 year: 1981 ident: rf21_317 publication-title: Lepr Rev – ident: rf37_332 doi: 10.1038/nature02326 – ident: rf2_298 doi: 10.1128/CMR.19.2.338-381.2006 – ident: rf31_326 doi: 10.1146/annurev.immunol.20.081501.125851 – ident: rf25_321 doi: 10.1111/j.1574-695X.2001.tb01586.x – ident: rf28_324 doi: 10.1093/nar/gkh005 – ident: rf4_300 doi: 10.1126/science.1681588 – ident: rf16_312 doi: 10.1038/sj.gene.6364274 – volume: 177 start-page: 133 year: 1998 ident: rf34_329 publication-title: J Infect Dis doi: 10.1086/513830 – volume: 149 start-page: 1470 year: 1992 ident: rf5_301 publication-title: J Immunol doi: 10.4049/jimmunol.149.4.1470 – volume: 71 start-page: 309 year: 2000 ident: rf23_319 publication-title: Lepr Rev – volume: 176 start-page: 530 year: 1997 ident: rf32_327 publication-title: J Infect Dis doi: 10.1086/517282 – ident: rf35_330 doi: 10.1002/gepi.1370120107 – ident: rf30_325 doi: 10.1038/nm864 |
SSID | ssj0004367 |
Score | 2.2831402 |
Snippet | Background. Leprosy is characterized by a spectrum of clinical manifestations that depend on the type of immune response against the pathogen. Patients may... Background. Leprosy is characterized by a spectrum of clinical manifestations that depend on the type of immune response against the pathogen. Patients may... Leprosy is characterized by a spectrum of clinical manifestations that depend on the type of immune response against the pathogen. Patients may undergo... |
SourceID | pubmedcentral proquest pubmed pascalfrancis crossref oup jstor istex |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 253 |
SubjectTerms | Adolescent Adult Bacteria Bacterial diseases Biological and medical sciences Case-Control Studies Child Child, Preschool Ethiopia Ethnic groups Ethnicity Female Genetic Predisposition to Disease Haplotypes Human bacterial diseases Humans Infant Infant, Newborn Infectious diseases Leprosy Leprosy - ethnology Leprosy - genetics Leprosy - immunology Leprosy - physiopathology Linkage Disequilibrium Male Medical genetics Medical sciences Microbial genetics Microsatellite Repeats Microsatellites Middle Aged Polymorphism, Genetic Polymorphism, Single Nucleotide rev genes Toll like receptors Toll-Like Receptor 2 - genetics Tropical bacterial diseases |
Title | Toll-Like Receptor 2 (TLR2) Polymorphisms Are Associated with Reversal Reaction in Leprosy |
URI | https://api.istex.fr/ark:/67375/HXZ-C27NC1R9-2/fulltext.pdf https://www.jstor.org/stable/30087656 https://www.ncbi.nlm.nih.gov/pubmed/18177245 https://www.proquest.com/docview/20231354 https://www.proquest.com/docview/70208814 https://pubmed.ncbi.nlm.nih.gov/PMC3077295 |
Volume | 197 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1537-6613 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004367 issn: 0022-1899 databaseCode: KQ8 dateStart: 19970401 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals Online customDbUrl: eissn: 1537-6613 dateEnd: 20240930 omitProxy: true ssIdentifier: ssj0004367 issn: 0022-1899 databaseCode: DIK dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1537-6613 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004367 issn: 0022-1899 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLaqTSAkhGAw6IDhB0CgKlPj-JI-Vu1QC92A0opuL5GTOKLaSKdeEOOH8Hs5juOk2YXbS1QlR6mV7_Pl2N85B6HnbuRGESxUHZ_TpkO1KKfFw8jxeJjENAn1HKjVFoe8N6ZvJ2xSq_1cUy2tluFe9OPKuJL_QRXuAa46SvYfkC1eCjfgN-ALV0AYrn-HMYDoDKYnuvaClqfM5g2il4yjwZBod__D7BRce_iS08XXRaM9VwUaVnQ-VFqWkSXYz4uGT9PGQMGwuqic95YRZHmSCSPhWi3sCU-52_6-0xt3s8UpzLhz5Rx9Kx_22p8PS1lSKVYEOgz3D0zATUnXT_1ut_9x3M82bfcaw1V4Xtmk0Po4x4RpriW8_Z3IxAYWuL6pl1QMzka9m7OQrA-1JslwPmsTk9L90oTQzM6nGKHcVA-sZty-MBMW-kStXIGBDLzqTSI415Uxuv13Zbytx4XNQq8bvFazyvxTZZGzqfvrd6t3tYGUt8_kAnphYsqnXOXfXJTprq17RnfRnRx03Dbsu4dqKt1CN0wJ0_MtdPMgF2fcR8cFHbGlIyb4lSbja1yhIrxN4ZKKWFMRWypiS0U8TXFOxQdo_GZ_1Ok5eekOJ2KeWDoxVVGYyCRhTOiKdIQKcJ1d5caRFDGlVHlCelz6MlI0VoQrTxEhJDjT0o09z9tGG-ksVY8QprCGDiXlsc8o9WlTZk59k8imVIlirTp6Yb91EOV57XV5ldMg01f4PDCY1NGzwu7MZHK5ZPEyg6p4LOcnWvcoWNCbHAcdIg477rAVkDrazrAsDL0ssyPjdbQD4F77-t0K5oWZZRu00JIggEFen9zJVEFXBgtwwzxGr7cQutiu74LFQ0OashG-Cx40ZXUkKnQqDHSC-eqTdPolSzQP8z_43mznTw1_jG6Vnf4J2ljOV-oprNWX4W7WcX4BXvHmnw |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Toll-Like+Receptor+2+%28TLR2%29+Polymorphisms+Are+Associated+with+Reversal+Reaction+in+Leprosy&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=BOCHUD%2C+Pierre-Yves&rft.au=HAWN%2C+Thomas+R&rft.au=ADEREM%2C+Alan&rft.au=SIDDIQUI%2C+M.+Ruby&rft.date=2008-01-15&rft.pub=University+of+Chicago+Press&rft.issn=0022-1899&rft.volume=197&rft.issue=2&rft.spage=253&rft.epage=261&rft_id=info:doi/10.1086%2F524688&rft.externalDBID=n%2Fa&rft.externalDocID=20028701 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon |